Need for circumspection in prescribing tumor necrosis factor inhibitors and other biologic response modifiers
Open Access
- 7 February 2002
- journal article
- editorial
- Published by Wiley in Arthritis Care & Research
- Vol. 47 (1), 1-4
- https://doi.org/10.1002/art1.10244
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Experience with etanercept in an academic medical center: Are infection rates increased?Arthritis & Rheumatism, 2002
- Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With EtanerceptMayo Clinic Proceedings, 2001
- TNF-α Inhibition: The Need for a Tumor Necrosis Factor ThermostatMayo Clinic Proceedings, 2001
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Anticytokine Therapy — A New Era in the Treatment of Rheumatoid Arthritis?New England Journal of Medicine, 1999
- Early aggressive DMARD therapy: The key to slowing disease progression in rheumatoid arthritisScandinavian Journal of Rheumatology, 1999
- Reduction in long‐term disability in patients with rheumatoid arthritis by disease‐modifying antirheumatic drug–based treatment strategiesArthritis & Rheumatism, 1996
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994
- Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritisArthritis & Rheumatism, 1990
- The development of disability in rheumatoid arthritisArthritis & Rheumatism, 1986